Net Income (Loss) Attributable to Parent in USD of Eiger BioPharmaceuticals, Inc. from 2012 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Eiger BioPharmaceuticals, Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2012 to Q4 2023.
  • Eiger BioPharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the quarter ending 31 Dec 2023 was -$13,454,000.000, a 46.5% increase year-over-year.
  • Eiger BioPharmaceuticals, Inc. Net Income (Loss) Attributable to Parent for the twelve months ending 31 Dec 2023 was -$74,963,000.000, a 22.5% increase year-over-year.
  • Eiger BioPharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2023 was -$74,963,000.000, a 22.5% increase from 2022.
  • Eiger BioPharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$96,776,000.000, a 185% decline from 2021.
  • Eiger BioPharmaceuticals, Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$33,917,000.000, a 47.9% increase from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

Eiger BioPharmaceuticals, Inc. Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q4 2023 -$74,963,000 -$13,454,000 +$11,684,000 +46.5% 01 Oct 2023 31 Dec 2023 10-K 08 Apr 2024
Q3 2023 -$86,647,000 -$18,030,000 +$9,081,000 +33.5% 01 Jul 2023 30 Sep 2023 10-Q 09 Nov 2023
Q2 2023 -$95,728,000 -$20,695,000 +$1,189,000 +5.4% 01 Apr 2023 30 Jun 2023 10-Q 09 Nov 2023
Q1 2023 -$96,917,000 -$22,784,000 -$141,000 -0.62% 01 Jan 2023 31 Mar 2023 10-Q 09 Nov 2023
Q4 2022 -$96,776,000 -$25,138,000 -$3,370,000 -15.5% 01 Oct 2022 31 Dec 2022 10-K 08 Apr 2024
Q3 2022 -$93,406,000 -$27,111,000 -$4,888,000 -22% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$88,518,000 -$21,884,000 -$2,710,000 -14.1% 01 Apr 2022 30 Jun 2022 10-Q 09 Nov 2023
Q1 2022 -$85,808,000 -$22,643,000 -$51,891,000 -1.8% 01 Jan 2022 31 Mar 2022 10-Q 09 Nov 2023
Q4 2021 -$33,917,000 -$21,768,000 -$2,962,000 -15.8% 01 Oct 2021 31 Dec 2021 10-K 17 Mar 2023
Q3 2021 -$30,955,000 -$22,223,000 -$6,543,000 -41.7% 01 Jul 2021 30 Sep 2021 10-Q 03 Nov 2022
Q2 2021 -$24,412,000 -$19,174,000 -$3,848,000 -25.1% 01 Apr 2021 30 Jun 2021 10-Q 03 Nov 2022
Q1 2021 -$20,564,000 $29,248,000 +$44,487,000 01 Jan 2021 31 Mar 2021 10-Q 03 Nov 2022
Q4 2020 -$65,051,000 -$18,806,000 -$1,886,000 -11.1% 01 Oct 2020 31 Dec 2020 10-K 17 Mar 2023
Q3 2020 -$63,165,000 -$15,680,000 +$2,936,000 +15.8% 01 Jul 2020 30 Sep 2020 10-Q 04 Nov 2021
Q2 2020 -$66,101,000 -$15,326,000 +$2,201,000 +12.6% 01 Apr 2020 30 Jun 2020 10-Q 04 Nov 2021
Q1 2020 -$68,302,000 -$15,239,000 +$1,950,000 +11.3% 01 Jan 2020 31 Mar 2020 10-Q 04 Nov 2021
Q4 2019 -$70,252,000 -$16,920,000 -$419,000 -2.5% 01 Oct 2019 31 Dec 2019 10-K 10 Mar 2022
Q3 2019 -$69,833,000 -$18,616,000 -$1,472,000 -8.6% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020
Q2 2019 -$68,361,000 -$17,527,000 -$7,612,000 -76.8% 01 Apr 2019 30 Jun 2019 10-Q 05 Nov 2020
Q1 2019 -$60,749,000 -$17,189,000 -$8,358,000 -94.6% 01 Jan 2019 31 Mar 2019 10-Q 05 Nov 2020
Q4 2018 -$52,391,000 -$16,501,000 -$5,608,000 -51.5% 01 Oct 2018 31 Dec 2018 10-K 09 Mar 2021
Q3 2018 -$46,783,000 -$17,144,000 -$7,974,000 -87% 01 Jul 2018 30 Sep 2018 10-Q 07 Nov 2019
Q2 2018 -$38,809,000 -$9,915,000 +$1,231,000 +11% 01 Apr 2018 30 Jun 2018 10-Q 07 Nov 2019
Q1 2018 -$40,040,000 -$8,831,000 +$2,408,000 +21.4% 01 Jan 2018 31 Mar 2018 10-Q 07 Nov 2019
Q4 2017 -$42,448,000 -$10,893,000 +$1,875,000 +14.7% 01 Oct 2017 31 Dec 2017 10-K 13 Mar 2020
Q3 2017 -$44,323,000 -$9,170,000 +$2,200,000 +19.3% 01 Jul 2017 30 Sep 2017 10-Q 09 Nov 2018
Q2 2017 -$46,523,000 -$11,146,000 +$2,055,000 +15.6% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018
Q1 2017 -$48,578,000 -$11,239,000 -$1,491,000 -15.3% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2018
Q4 2016 -$47,087,000 -$12,768,000 -$23,171,000 -2.2% 01 Oct 2016 31 Dec 2016 10-K 14 Mar 2019
Q3 2016 -$23,916,000 -$11,370,000 -$4,974,000 -77.8% 01 Jul 2016 30 Sep 2016 10-Q 09 Nov 2017
Q2 2016 -$18,942,000 -$13,201,000 +$3,324,000 +20.1% 01 Apr 2016 30 Jun 2016 10-Q 11 Aug 2017
Q1 2016 -$22,266,000 -$9,748,000 -$8,944,000 -11.1% 01 Jan 2016 31 Mar 2016 10-Q 12 May 2017
Q4 2015 -$13,322,000 $10,403,000 -$10,593,000 -50.5% 01 Oct 2015 31 Dec 2015 10-K 09 Mar 2018
Q3 2015 -$2,729,000 -$6,396,000 +$1,962,000 +23.5% 01 Jul 2015 30 Sep 2015 10-Q 09 Nov 2015
Q2 2015 -$4,691,000 -$16,525,000 -$9,533,000 -1.4% 01 Apr 2015 30 Jun 2015 10-Q 11 Aug 2015
Q1 2015 $4,842,000 -$804,000 +$6,358,000 +88.8% 01 Jan 2015 31 Mar 2015 10-Q 16 May 2016
Q4 2014 -$1,516,000 $20,996,000 +$8,132,863 +63.2% 01 Oct 2014 31 Dec 2014 10-K 23 Mar 2017
Q3 2014 -$9,648,863 -$8,358,000 -$2,905,000 -53.3% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015
Q2 2014 -$6,743,863 -$6,992,000 -$2,098,000 -42.9% 01 Apr 2014 30 Jun 2014 10-Q 11 Aug 2015
Q1 2014 -$4,645,863 -$7,162,000 -$3,693,000 -1.1% 01 Jan 2014 31 Mar 2014 10-Q 13 May 2014
Q4 2013 -$952,863 $12,863,137 01 Oct 2013 31 Dec 2013 8-K/A 17 Jun 2016
Q3 2013 -$5,453,000 01 Jul 2013 30 Sep 2013 10-Q 12 Nov 2014
Q2 2013 -$4,894,000 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014
Q1 2013 -$3,469,000 01 Jan 2013 31 Mar 2013 10-Q 13 May 2014

Eiger BioPharmaceuticals, Inc. Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$74,963,000 +$21,813,000 +22.5% 01 Jan 2023 31 Dec 2023 10-K 08 Apr 2024
2022 -$96,776,000 -$62,859,000 -1.9% 01 Jan 2022 31 Dec 2022 10-K 08 Apr 2024
2021 -$33,917,000 +$31,134,000 +47.9% 01 Jan 2021 31 Dec 2021 10-K 17 Mar 2023
2020 -$65,051,000 +$5,201,000 +7.4% 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2023
2019 -$70,252,000 -$17,861,000 -34.1% 01 Jan 2019 31 Dec 2019 10-K 10 Mar 2022
2018 -$52,391,000 -$9,943,000 -23.4% 01 Jan 2018 31 Dec 2018 10-K 09 Mar 2021
2017 -$42,448,000 +$4,639,000 +9.9% 01 Jan 2017 31 Dec 2017 10-K 13 Mar 2020
2016 -$47,087,000 -$33,765,000 -2.5% 01 Jan 2016 31 Dec 2016 10-K 14 Mar 2019
2015 -$13,322,000 -$11,806,000 -7.8% 01 Jan 2015 31 Dec 2015 10-K 09 Mar 2018
2014 -$1,516,000 -$563,137 -59.1% 01 Jan 2014 31 Dec 2014 10-K 23 Mar 2017
2013 -$952,863 +$14,764,137 +93.9% 01 Jan 2013 31 Dec 2013 8-K/A 17 Jun 2016
2012 -$15,717,000 01 Jan 2012 31 Dec 2012 10-K 31 Mar 2015
* An asterisk sign (*) next to the value indicates that the value is likely invalid.